Examining the impact of anesthesia on brain development in children with retinoblastoma
Official title: Incidence of Neurocognitive Deficits in Patients After Treatment for Retinoblastoma With Multiple Anesthesia Exposures
Run by Memorial Sloan Kettering Cancer Center · NCT03546387 · Data updated 2026-11-12
This study is trying to see if having anesthesia for retinoblastoma treatment affects how well children think and develop compared to those who haven't had anesthesia.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Years to 17 Years |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, Radiation |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | May 7, 2018 |
| Main results expected | May 7, 2027 |
| Study ends | May 7, 2027 |
| Registry record updated | June 3, 2026 |
| Trial ID | NCT03546387 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 6 to 17 years who have been treated for retinoblastoma and have had multiple exposures to anesthesia.
✕Probably not a fit
Patients with secondary diseases associated with developmental delays or those who have undergone certain treatments or surgeries unrelated to retinoblastoma may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the effects of multiple anesthesia exposures on cognitive function in children treated for retinoblastoma. It compares neurodevelopment outcomes in children who have undergone anesthesia for retinoblastoma treatment with those who have never been exposed to anesthesia. Various cognitive assessments, including the Wechsler Intelligence Scale for Children and other developmental tests, will be utilized to evaluate differences in brain development. The study is conducted at Memorial Sloan Kettering Cancer Center, focusing on a specific age group of pediatric patients.
Why it matters
Potential benefit: If successful, this study could provide insights into the cognitive risks associated with anesthesia in young patients, potentially guiding safer treatment protocols.
How similar studies have gone: While there have been studies examining the effects of anesthesia on cognitive function, this specific focus on pediatric retinoblastoma patients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 6 and \< 17 years old Exclusion Criteria: * Diagnosis of any secondary disease associated with developmental delay * History of second cancer diagnosis * Legal Blindness * Past surgery of any type, with the exception of enucleation for retinoblastoma * Past exposure to anesthesia for surgical intervention * More than one anesthesia encounter for surgical intervention before diagnosis at MSK * Past External Beam Radiation for treatment of retinoblastoma * Past systemic chemotherapy * Non-native speaker of English; however, children whose parents speak only Spanish will be included, because the tests for parents are available in Spanish
Where it's running
-
Memorial Sloan Kettering Cancer Center
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Vittoria Arslan Carlon, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Vittoria Arslan Carlon, MD
- Email: arslancv@mskcc.org
- Phone: 212-639-2680
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High-dose Topotecan treatment for recurrent retinoblastoma with vitreous seeds
This study is testing whether high-dose Topotecan can help patients with recurrent retinoblastoma and vitreous seeds keep their eye while fighting the tumor.
-
Linking RB1 genetic changes to eye tumors and metastasis
We will use targeted long-read genetic sequencing on people with retinoblastoma to see if specific RB1 mutations match tumor features and the risk of spread.
-
Treatment for advanced retinoblastoma using a chemoplaque
This study is testing a new treatment using a special chemotherapy patch for young children with advanced retinoblastoma to see if it helps fight the cancer while keeping their vision safe.
-
New treatment for children with hard-to-treat retinoblastoma
This study is testing a new drug for children with hard-to-treat eye cancer to see if it works better and has fewer side effects than standard chemotherapy.
-
Understanding the incidence and outcomes of trilateral retinoblastoma
This study looks at how common trilateral retinoblastoma is and how well patients survive, comparing data from different countries to see if there are differences based on income levels.
-
Chemotherapy for high-risk retinoblastoma after eye removal
This study is testing if giving chemotherapy after removing the eye can help prevent high-risk retinoblastoma from coming back in children with Stage I disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.